Journal DOI 10.68956/journal.human-performance-futures

Creative Commons source reading · Heat, altitude and environment

Thermophysiological and perceptual responses to exercise heat stress in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor

Lauren J. Clayton; Jo Corbett; Anthony I. Shepherd; Heather Massey; Don S. Urquhart; Neil Maxwell; Gary Connett; Mark Allenby; Julian Legg; Thomas Daniels; Zoe L. Saynor

Originally published in Exp Physiol · 2026-09-12

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

AbstractThe objective of this study was to investigate thermophysiological and perceptual responses to exercise heat stress in people with cystic fibrosis (pwCF) on Elexacaftor/Tezacaftor/Ivacaftor (ETI) versus healthy controls, and to explore their lived experiences of heat stress. This mixed‐methods, multi‐study project comprised: (i) a laboratory study where pwCF (n = 6) and matched controls (n = 6) completed two 30 minutes cycling bouts in the heat (35°C, 30% relative humidity), at 150 and 250 W·m−2 metabolic heat production. Measures included sweat sodium chloride ([Na+Cl−]), local and whole body sweat rate, deep body and skin temperatures, heart rate (HR), forearm and finger skin blood flow (SkBF), and perceptual responses (exertion, thermal sensation and comfort, thirst, heat‐illness symptom index (HISI)); and (ii) a pilot…

DISCUSSION

This study is the first to adopt a mixed‐methods, multi‐study approach to investigate thermophysiological and perceptual responses to laboratory‐controlled exercise heat‐stress in pwCF receiving CFTR modulator therapy, alongside exploratory pilot survey insights into real‐world sweating perceptions, as well as hydration and salt replacement strategies. We provide the first tightly controlled laboratory data, providing comprehensive and contemporary characterisation of thermoregulation, sweating and heat‐illness vulnerability in pwCF treated with ETI, as well as self‐reported experiences. Across both studies, four principal novel findings emerged: during prolonged exercise in the heat at a fixed rate of metabolic heat production, (1) pwCF on ETI demonstrated thermoregulatory and perceptual responses that were not different from healthy…

Laboratory findings: normalisation of thermoregulatory and sweating responses du

Our laboratory study provides the first controlled physiological evidence that pwCF on ETI exhibit thermoregulatory and, for the most part, perceptual responses that are not different from healthy matched controls during prolonged cycling in the heat (35°C, 30% RH) at a fixed metabolic heat production (150 W·m− 2). No group differences were observed for sweat [Na+Cl−], whole‐body or local sweat rates, core or skin temperatures, mean body temperature, heart rate, or cutaneous skin blood flow. These findings contrast sharply with the limited existing research before the availability of CFTR modulator therapy (Brown et al., 2011; Orenstein et al., 1983). In the only prior study to have examined exercise sweat [Na+Cl−] in pwCF, significantly elevated exercise sweat [Na+Cl−] in pwCF during 70 minutes of cycling at 50% V˙O2peak in the heat…

Editorial reading guide

  • Was the outcome a biological marker, subjective response or meaningful performance change?
  • What dose, timing, population and setting bound the practical conclusion?